MannKind Corp. (NASDAQ: MNKD) , the maker of the inhaled insulin product Afrezza, saw its shares rise by another 40% today. As a result, the biotech’s share price has now gained an impressive 126% since the start of October — thanks to the U.S. Food and Drug Administration approving a favorable label change for Afrezza, as well as a successful common-stock-for-warrant swap that improved the company’s capital structure.
Image source: Getty Images.
Because of Afrezza’s anemic sales since its launch, MannKind seemed to be on the brink of collapse. The company, after all, had essentially exhausted the majority of its financial resources bringing Afrezza to market in the first place, and therefore needed the drug to get off to a quick start. Based on MannKind’s recent momentum, however, investors now appear to think that these recent label changes will finally unlock Afrezza’s megablockbuster potential.
While a less restrictive label for Afrezza is certainly good news for MannKind and its shareholders, the fact remains that this beaten-down biotech needs to recapitalize in a significant way. MannKind, after all, exited the most recent quarter with less than $44 million remaining in cash. That’s nowhere near enough to ramp up Afrezza’s commercial launch, at least in a way that could spark the leap in sales needed to make this company viable on a long-term basis.
So, even though MannKind does have some funds remaining through its current at-the-market (ATM) facility, investors should probably brace themselves for a sizable secondary offering soon — especially after this rapid rise in the company’s share price. In other words, MannKind’s rocket-like trajectory may start to taper off, once the company does the inevitable by raising capital via a public offering.
10 stocks we like better than MannKind Corporation
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and MannKind Corporation wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.